NCT05732454
Introducing a clinical trial for people with moderate-to-severe eczema (atopic dermatitis)
Atopic dermatitis (AD), the most common form of eczema, causes itchy, dry, cracked, and red skin. It is among the most common dermatological conditions worldwide.
This study is evaluating an oral, steroid-free investigational medication to see if it may safely and effectively reduce symptoms of AD.
The study medication is thought to work by stopping your immune system from creating unnecessary inflammation in your skin. This reduction in inflammation is thought to reduce the itchiness and pain associated with AD.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
Get started — See if you may qualify
A first step as you consider this study is to answer a 5-minute questionnaire about your health and medical history online. If your answers show the study might be a good fit for you, you may choose to be referred to a clinical research site that you select.
You will then be asked to provide your contact information for a member of the research study staff to contact you and discuss the next steps. If you’re interested, they will do a more detailed review of your medical history to see if you are able to participate. Only the study staff can determine if you meet the study’s eligibility criteria and are able to enroll in the study.
Your answers to these initial questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the clinical research site that you select. Pfizer study team members and our partners will have access to reports containing collected data that will not be linked back to you.
What to expect
About Atopic Dermatitis
Atopic dermatitis (AD, also known as atopic eczema) is a common and chronic skin disease that causes people to experience dry, itchy and discolored patches of skin. Skin normally forms a barrier between the inside of your body and the outside environment. In people with AD, it is thought that this barrier is disrupted, and that the immune system behaves harmfully.
Currently, there is no single systemic treatment (a treatment affecting the whole body) that is viewed as safe and effective for all AD patients. Existing treatments for moderate-to-severe AD can only be used short-term because the treatments are inconvenient or cause side-effects that patients can’t manage. Therefore, there is a need for better treatment options for AD.
Frequently asked questions
Are there any risks?
There are some risks associated with taking part in this study. Taking the study treatment (oral investigational medication or placebo) could make your condition worsen, get better, or stay the same.
Side effects of the study medicine may be mild or serious. A full description of the risks of taking part in this study are given in the informed consent document, which you will be provided with before agreeing to take part in the study.
Your health will be monitored throughout the study. If your health gets worse, a decision will be made between you, the study doctor and the study team about whether you should continue to participate in the study. Your health will be prioritized.
What is a placebo?
A placebo does not contain any active ingredients, but the study medication and the placebo look alike.
What is double blind?
Neither you nor the study team will know if the study medication or the placebo is being given.
Are there any benefits?
You may not receive any benefit from taking part in this study. However, by contributing to research of a treatment for AD, you may help future patients.
